Serum-Amyloid-A to High-Density-Lipoprotein-Cholesterol Ratio: superior biomarker for early diagnosis of coronary artery disease with clinically relevant stenoses and development of machine learning diagnostic model

血清淀粉样蛋白A与高密度脂蛋白胆固醇比值:用于早期诊断具有临床意义的冠状动脉狭窄的优良生物标志物,并可用于开发机器学习诊断模型

阅读:2

Abstract

BACKGROUND: This study aimed to evaluate the early diagnostic value of Serum-Amyloid-A to High-Density-Lipoprotein-Cholesterol Ratio (SHR) for coronary artery disease (CAD) with clinically relevant stenoses and develop a machine learning diagnostic model based on eXtreme Gradient Boosting (XGBoost). METHODS AND RESULTS: Data from 1,108 CAD patients (with coronary luminal diameter stenosis ≥50% or evidence of functional myocardial ischemia) and 962 controls were retrospectively analyzed. Receiver operating characteristic (ROC) analysis showed SHR (area under the curve (AUC) = 0.769) outperformed C-reactive protein (CRP) (p = 0.006) and Serum amyloid A (SAA) (p < 0.001). Four XGBoost models were constructed, and the best model (CRP + SAA + SHR + 13 other variables) achieved an AUC of 0.876. SHR correlated nonlinearly with age (p < 0.001), and its diagnostic efficacy was higher in younger patients (40 years old, OR = 16.29) than in older adults (80 years old, OR = 4.37). Machine learning models can address the decline in diagnostic capability of SHR in the elderly population. CONCLUSION: SHR is a superior composite biomarker for early diagnosis of CAD with clinically relevant stenoses, outperforming CRP and SAA. Machine learning model integrating multiple indicators shows excellent diagnostic performance. Elevated SHR indicates higher CAD risk in younger individuals, providing a new strategy for early screening of CAD with clinically relevant stenoses.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。